COMP <GO>
VCEL vs ABBV // RETURN ON INVESTED CAPITAL (ROIC)
Vericel Corporation (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: VCEL 5
— ABBV 8
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: ABBV
LAST: $42.91 (+4.43%) • MKT CAP: $2.20B
roic
3.40%
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
roic
29.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (VCEL VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | VCEL | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 74.40% | 70.20% | +4.20 | VCEL | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | 3.40% | 29.00% | -25.60 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 61.4x | 33.3x | +28.10 | ABBV | /valuation <GO> |
| Free Cash Flow Yield | 1.13% | 3.47% | -2.34 | ABBV | /fcf-yield <GO> |
| Operating Margin | 4.00% | 24.60% | -20.60 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 6.00% | 6.90% | -0.90 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 16.50% | 8.60% | +7.90 | VCEL | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 9.94 | 5.33 | +4.61 | VCEL | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | VCEL | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 46.2 | 65.1 | -18.94 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 111.7x | 113.1x | -1.40 | VCEL | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.20B | $513.86B | -$511.66B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | VCEL REV | ABBV REV | VCEL GROSS % | ABBV GROSS % | VCEL FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $276.3M | $61.16B | 74.4% | 70.2% | $24.7M | $17.82B |
| FY 2024 | $237.2M | $56.33B | 72.6% | 70.0% | -$5.8M | $17.83B |
| FY 2023 | $197.5M | $54.32B | — | — | $35.3M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
VCEL // BETA —
ABBV // BETA 1.15